Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis

Lancet Rheumatol. 2024 May;6(5):e314-e327. doi: 10.1016/S2665-9913(24)00035-3. Epub 2024 Apr 1.

Abstract

Proteinase 3 (PR3)-specific antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is one of two major ANCA-associated vasculitis variants and is pathogenically linked to granulomatosis with polyangiitis (GPA). GPA is characterised by necrotising granulomatous inflammation that preferentially affects the respiratory tract. The small vessel vasculitis features of GPA are shared with microscopic polyangiitis. Necrotising granulomatous inflammation of GPA can lead to PR3-ANCA and small vessel vasculitis via activation of neutrophils and monocytes. B cells are central to the pathogenesis of PR3-ANCA-associated vasculitis. They are targeted successfully by remission induction and maintenance therapy with rituximab. Relapses of PR3-ANCA-associated vasculitis and toxicities associated with current standard therapy contribute substantially to remaining mortality and damage-associated morbidity. More effective and less toxic treatments are sought to address this unmet need. Advances with cellular and novel antigen-specific immunotherapies hold promise for application in autoimmune disease, including PR3-ANCA-associated vasculitis. This Series paper describes the inter-related histopathological and clinical features, pathophysiology, as well as current and future targeted treatments for PR3-ANCA-associated vasculitis.

Publication types

  • Review

MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / immunology
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / pathology
  • Antibodies, Antineutrophil Cytoplasmic / immunology
  • Granulomatosis with Polyangiitis / drug therapy
  • Granulomatosis with Polyangiitis / immunology
  • Granulomatosis with Polyangiitis / pathology
  • Granulomatosis with Polyangiitis / therapy
  • Humans
  • Myeloblastin / immunology
  • Rituximab / therapeutic use

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Myeloblastin
  • Rituximab